LLY
754.57
-0.24%↓
JNJ
178.08
-0.17%↓
ABBV
218.3
-0.8%↓
UNH
352.9
-0.29%↓
AZN
79.54
-1.96%↓
LLY
754.57
-0.24%↓
JNJ
178.08
-0.17%↓
ABBV
218.3
-0.8%↓
UNH
352.9
-0.29%↓
AZN
79.54
-1.96%↓
LLY
754.57
-0.24%↓
JNJ
178.08
-0.17%↓
ABBV
218.3
-0.8%↓
UNH
352.9
-0.29%↓
AZN
79.54
-1.96%↓
LLY
754.57
-0.24%↓
JNJ
178.08
-0.17%↓
ABBV
218.3
-0.8%↓
UNH
352.9
-0.29%↓
AZN
79.54
-1.96%↓
LLY
754.57
-0.24%↓
JNJ
178.08
-0.17%↓
ABBV
218.3
-0.8%↓
UNH
352.9
-0.29%↓
AZN
79.54
-1.96%↓
24h
Current
Min
Max
Income | 78M 75M |
---|---|
Sales | 5.5M 26M |
Profit margin | 288.656 |
Employees | 59 |
EBITDA | -73M -71M |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +209.68% upside |
Next Earnings | 11 lis 2025 |
---|
Market Cap | -172M 468M |
---|---|
Previous open | 0 |
Previous close | 0 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
27 lut 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 24 USD 209.68%
High 29 USD
Low 18 USD
Based on 7 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
7 ratings
7
Buy
0
Hold
0
Sell
Based on 7 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$